Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

TON - June 2020, Vol 13, No 3

TON June 2020, Vol 13, No 3 Cover

The combination of the checkpoint inhibitor durvalumab, the poly ADP-ribose polymerase (PARP) inhibitor olaparib, and chemotherapy with paclitaxel used as neoadjuvant therapy improved the pathologic complete response of patients with high-risk HER2-negative stage II or III breast cancer compared with the physician’s choice of chemotherapy.
Page 1 of 2
Results 1 - 10 of 17